JP2009143964A5 - - Google Patents

Download PDF

Info

Publication number: JP2009143964A5
Authority: JP; Japan
Prior art keywords: pharmaceutically acceptable; release matrix; patient; opioid; controlled release
Prior art date: 2009-03-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

JP2009077801A

Other languages

English (en)

Japanese (ja)

Other versions

JP2009143964A (ja

Filing date

2009-03-26

Publication date

2010-02-25

2009-03-26 Application filed filed Critical

2009-07-02 Publication of JP2009143964A publication Critical patent/JP2009143964A/ja

2010-02-25 Publication of JP2009143964A5 publication Critical patent/JP2009143964A5/ja

Status Withdrawn legal-status Critical Current

Links

239000003401 opiate antagonist Substances 0.000 claims description 5
239000008187 granular material Substances 0.000 claims 9
239000011159 matrix material Substances 0.000 claims 8
150000003839 salts Chemical class 0.000 claims 8
238000013270 controlled release Methods 0.000 claims 6
239000000203 mixture Substances 0.000 claims 5
239000011248 coating agent Substances 0.000 claims 4
238000000576 coating method Methods 0.000 claims 4
239000003402 opiate agonist Substances 0.000 claims 4
239000012729 immediate-release (IR) formulation Substances 0.000 claims 3
229920002678 cellulose Polymers 0.000 claims 2
239000001913 cellulose Substances 0.000 claims 2
UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 3
229960004127 naloxone Drugs 0.000 description 3
-1 nalolphine Chemical compound 0.000 description 2
YQYVFVRQLZMJKJ-JBBXEZCESA-N (+)-cyclazocine Chemical compound C([C@@]1(C)C2=CC(O)=CC=C2C[C@@H]2[C@@H]1C)CN2CC1CC1 YQYVFVRQLZMJKJ-JBBXEZCESA-N 0.000 description 1
OIJXLIIMXHRJJH-KNLIIKEYSA-N Diprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)C(C)(C)O)OC)CN2CC1CC1 OIJXLIIMXHRJJH-KNLIIKEYSA-N 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
229950002213 cyclazocine Drugs 0.000 description 1
229950002494 diprenorphine Drugs 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
YGSVZRIZCHZUHB-COLVAYQJSA-N metazocine Chemical compound C1C2=CC=C(O)C=C2[C@]2(C)CCN(C)[C@@]1([H])[C@@H]2C YGSVZRIZCHZUHB-COLVAYQJSA-N 0.000 description 1
229950009131 metazocine Drugs 0.000 description 1
DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 1
229960003086 naltrexone Drugs 0.000 description 1
239000003887 narcotic antagonist Substances 0.000 description 1
VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
229960005301 pentazocine Drugs 0.000 description 1

JP2009077801A 2001-05-11 2009-03-26 乱用耐性のオピオイド投薬形態 Withdrawn JP2009143964A (ja)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US29043801P	2001-05-11	2001-05-11

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2002588977A Division JP2005515960A (ja)	2001-05-11	2002-05-10	乱用耐性のオピオイド投薬形態

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2012276500A Division JP2013053165A (ja)	2001-05-11	2012-12-19	乱用耐性のオピオイド投薬形態

Publications (2)

Publication Number	Publication Date
JP2009143964A JP2009143964A (ja)	2009-07-02
JP2009143964A5 true JP2009143964A5 (2)	2010-02-25

Family

ID=23115998

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
JP2002588977A Pending JP2005515960A (ja)	2001-05-11	2002-05-10	乱用耐性のオピオイド投薬形態
JP2009077801A Withdrawn JP2009143964A (ja)	2001-05-11	2009-03-26	乱用耐性のオピオイド投薬形態
JP2012276500A Pending JP2013053165A (ja)	2001-05-11	2012-12-19	乱用耐性のオピオイド投薬形態

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
JP2002588977A Pending JP2005515960A (ja)	2001-05-11	2002-05-10	乱用耐性のオピオイド投薬形態

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
JP2012276500A Pending JP2013053165A (ja)	2001-05-11	2012-12-19	乱用耐性のオピオイド投薬形態

Country Status (10)

Country	Link
US (6)	US20030004177A1 (2)
EP (1)	EP1389092B1 (2)
JP (3)	JP2005515960A (2)
CN (2)	CN1592609A (2)
AT (1)	ATE345112T1 (2)
AU (1)	AU2002303718B2 (2)
CA (2)	CA2446738C (2)
DE (1)	DE60216078T2 (2)
ES (1)	ES2275868T3 (2)
WO (1)	WO2002092059A1 (2)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6375957B1 (en)	1997-12-22	2002-04-23	Euro-Celtique, S.A.	Opioid agonist/opioid antagonist/acetaminophen combinations
JP2001526228A (ja)	1997-12-22	2001-12-18	ユーロ−セルティーク，エス．エイ．	オピオイド作動薬／拮抗薬の併用
US10179130B2 (en)	1999-10-29	2019-01-15	Purdue Pharma L.P.	Controlled release hydrocodone formulations
KR100889069B1 (ko)	1999-10-29	2009-03-17	유로-셀티크 소시에떼 아노뉨	서방성 하이드로코돈 제형
HU229705B1 (en)	2000-02-08	2014-05-28	Euro Celtique Sa	Tamper-resistant oral opioid agonist formulations
AU2738302A (en)	2000-10-30	2002-05-15	Euro Celtique Sa	Controlled release hydrocodone formulations
US8394813B2 (en)	2000-11-14	2013-03-12	Shire Llc	Active agent delivery systems and methods for protecting and administering active agents
CN1525851A (zh)	2001-05-11	2004-09-01	��ҩ��޹�˾	抗滥用阿片样物质控释剂型
JP2005515960A (ja) *	2001-05-11	2005-06-02	エンドーファーマシューティカルズ，インコーポレイティド	乱用耐性のオピオイド投薬形態
AU2002339378A1 (en) *	2001-05-22	2002-12-03	Euro-Celtique	Compartmentalized dosage form
DE60223254T2 (de) *	2001-07-06	2008-08-14	Penwest Pharmaceuticals Co.	Verzögert freisetzende formulierungen von oxymorphon
JP2005515966A (ja)	2001-07-06	2005-06-02	エンドーファーマシューティカルズ，インコーポレイティド	鎮痛薬としての使用のための６−ヒドロキシ−オキシモルホンの経口投与
US8329216B2 (en)	2001-07-06	2012-12-11	Endo Pharmaceuticals Inc.	Oxymorphone controlled release formulations
SI1416842T1 (sl) *	2001-07-18	2009-06-30	Euro Celtique Sa	Farmacevtske kombinacije oksikodona in naloksona
ATE431738T1 (de)	2001-08-06	2009-06-15	Euro Celtique Sa	Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
US7141250B2 (en) *	2001-08-06	2006-11-28	Euro-Celtique S.A.	Pharmaceutical formulation containing bittering agent
US7842307B2 (en) *	2001-08-06	2010-11-30	Purdue Pharma L.P.	Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
AU2002324624A1 (en) *	2001-08-06	2003-02-24	Euro-Celtique S.A.	Sequestered antagonist formulations
US20030044458A1 (en) *	2001-08-06	2003-03-06	Curtis Wright	Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US7157103B2 (en) *	2001-08-06	2007-01-02	Euro-Celtique S.A.	Pharmaceutical formulation containing irritant
US7332182B2 (en)	2001-08-06	2008-02-19	Purdue Pharma L.P.	Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US7144587B2 (en) *	2001-08-06	2006-12-05	Euro-Celtique S.A.	Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
US20030068375A1 (en)	2001-08-06	2003-04-10	Curtis Wright	Pharmaceutical formulation containing gelling agent
US20060014697A1 (en) *	2001-08-22	2006-01-19	Travis Mickle	Pharmaceutical compositions for prevention of overdose or abuse
US7169752B2 (en)	2003-09-30	2007-01-30	New River Pharmaceuticals Inc.	Compounds and compositions for prevention of overdose of oxycodone
DE10141650C1 (de)	2001-08-24	2002-11-28	Lohmann Therapie Syst Lts	Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
AU2002337686B2 (en) *	2001-09-26	2008-05-15	Penwest Pharmaceuticals Company	Opioid formulations having reduced potential for abuse
EP1450824A4 (en) *	2001-11-02	2005-09-28	Elan Corp Plc	PHARMACEUTICAL COMPOSITION
EP1492505B1 (en)	2002-04-05	2015-06-03	Euro-Celtique S.A.	Pharmaceutical preparation containing oxycodone and naloxone
US7815934B2 (en)	2002-09-20	2010-10-19	Alpharma Pharmaceuticals, Llc	Sequestering subunit and related compositions and methods
EP1551402A4 (en) *	2002-09-23	2009-05-27	Verion Inc	PHARMACEUTICAL COMPOSITIONS NOT INDUCING ABUSE
DE10250088A1 (de) *	2002-10-25	2004-05-06	Grünenthal GmbH	Gegen Missbrauch gesicherte Darreichungsform
ATE482695T1 (de)	2002-12-13	2010-10-15	Durect Corp	Orale darreichungsform mit flüssigen hochviskosen trägersystemen
AU2003301121A1 (en) *	2002-12-18	2004-07-14	Pain Therapeutics, Inc.	Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
US7524515B2 (en) *	2003-01-10	2009-04-28	Mutual Pharmaceuticals, Inc.	Pharmaceutical safety dosage forms
US20040202717A1 (en)	2003-04-08	2004-10-14	Mehta Atul M.	Abuse-resistant oral dosage forms and method of use thereof
MY135852A (en)	2003-04-21	2008-07-31	Euro Celtique Sa	Pharmaceutical products
EP1615625A4 (en)	2003-04-21	2010-12-15	Euro Celtique Sa	SAFETY DOSING FORM WITH COEXTRUDED PARTICLES OF AN UNWANTED MEDIUM AND METHOD OF MANUFACTURING THEREOF
US8790689B2 (en)	2003-04-30	2014-07-29	Purdue Pharma L.P.	Tamper resistant transdermal dosage form
RS20050812A (sr)	2003-04-30	2007-12-31	Purdue Pharma L.P.,	Transdermalni dozni oblik otporan na promene
US7182955B2 (en)	2003-04-30	2007-02-27	3M Innovative Properties Company	Abuse-resistant transdermal dosage form
DE10361596A1 (de)	2003-12-24	2005-09-29	Grünenthal GmbH	Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de)	2005-02-04	2006-08-10	Grünenthal GmbH	Bruchfeste Darreichungsformen mit retardierter Freisetzung
US7201920B2 (en) *	2003-11-26	2007-04-10	Acura Pharmaceuticals, Inc.	Methods and compositions for deterring abuse of opioid containing dosage forms
CA2548834C (en) *	2003-12-09	2009-08-11	Euro-Celtique S.A.	Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
US8883204B2 (en)	2003-12-09	2014-11-11	Purdue Pharma L.P.	Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
RS50817B (sr) *	2004-03-30	2010-08-31	Euro-Celtique S.A.	Dozni oblik otporan na promene koji sadrži adsorbenti i sredstvo sa suprotnim dejstvom
US7404970B2 (en) *	2004-04-13	2008-07-29	Konec, Inc.	Pain relief composition, method to form same, and method to use same
EP1604666A1 (en) *	2004-06-08	2005-12-14	Euro-Celtique S.A.	Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1604667A1 (en) *	2004-06-08	2005-12-14	Euro-Celtique S.A.	Opioids for the treatment of the restless leg syndrome
CA2916869A1 (en)	2004-06-12	2005-12-29	Jane C. Hirsh	Abuse-deterrent drug formulations
DE102004032049A1 (de)	2004-07-01	2006-01-19	Grünenthal GmbH	Gegen Missbrauch gesicherte, orale Darreichungsform
US20070231268A1 (en) *	2004-11-24	2007-10-04	Acura Pharmaceuticals, Inc.	Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060177380A1 (en) *	2004-11-24	2006-08-10	Acura Pharmaceuticals, Inc.	Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20080152595A1 (en) *	2004-11-24	2008-06-26	Acura Pharmaceuticals, Inc.	Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060110327A1 (en) *	2004-11-24	2006-05-25	Acura Pharmaceuticals, Inc.	Methods and compositions for deterring abuse of orally administered pharmaceutical products
CA2594373A1 (en) *	2005-01-28	2006-08-03	Euro-Celtique S.A.	Alcohol resistant dosage forms
DE102005005449A1 (de)	2005-02-04	2006-08-10	Grünenthal GmbH	Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
EP1702558A1 (en)	2005-02-28	2006-09-20	Euro-Celtique S.A.	Method and device for the assessment of bowel function
EP1695700A1 (en) *	2005-02-28	2006-08-30	Euro-Celtique S.A.	Dosage form containing oxycodone and naloxone
US20070020339A1 (en) *	2005-07-20	2007-01-25	Pharmorx Inc.	Compositions and methods for controlling abuse of medications
US8497258B2 (en)	2005-11-12	2013-07-30	The Regents Of The University Of California	Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US20070185145A1 (en) *	2006-02-03	2007-08-09	Royds Robert B	Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
ZA200807571B (en) *	2006-03-01	2009-08-26	Ethypharm Sa	Crush-resistant tablets intended to prevent accidental misuse and unlawful diversion
US20070212414A1 (en) *	2006-03-08	2007-09-13	Penwest Pharmaceuticals Co.	Ethanol-resistant sustained release formulations
CA2645855C (en)	2006-03-16	2015-02-03	Tris Pharma, Inc.	Modified release formulations containing drug-ion exchange resin complexes
EP2007389A2 (en) *	2006-04-14	2008-12-31	Shire LLC	Compositions and methods for enhancing analgesic potency of covalently bound compounds, attenuating its adverse side effects, and preventing their abuse
US20080069891A1 (en)	2006-09-15	2008-03-20	Cima Labs, Inc.	Abuse resistant drug formulation
SI2719378T1 (sl)	2006-06-19	2016-11-30	Alpharma Pharmaceuticals Llc	Farmacevtski sestavki
SA07280459B1 (ar)	2006-08-25	2011-07-20	بيورديو فارما إل. بي.	أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
WO2008027442A2 (en) *	2006-08-30	2008-03-06	Theraquest Biosciences, Llc	Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use
EP1897544A1 (en) *	2006-09-05	2008-03-12	Holger Lars Hermann	Opioid agonist and antagonist combinations
US8445018B2 (en)	2006-09-15	2013-05-21	Cima Labs Inc.	Abuse resistant drug formulation
WO2008063301A2 (en) *	2006-10-11	2008-05-29	Alpharma, Inc.	Pharmaceutical compositions
CA2677690C (en) *	2007-02-12	2012-05-15	James V. Winkler	Treatment of comorbid premature ejaculation and erectile dysfunction
CN101674728A (zh) *	2007-02-12	2010-03-17	Dmi生物科学公司	降低曲马多的副作用
US20090124650A1 (en) *	2007-06-21	2009-05-14	Endo Pharmaceuticals, Inc.	Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
AU2014250614B2 (en) *	2007-09-04	2016-11-10	Alpharma Pharmaceuticals, Llc	A multilayer pharmaceutical composition comprising an antagonist in a first layer and an agonist in a second layer
AU2008296905A1 (en) *	2007-09-04	2009-03-12	Alpharma Pharmaceuticals, Llc	A multilayer pharmaceutical composition comprising an antagonist in a first layer and an agonist in a second layer
EP2219622A1 (en)	2007-12-06	2010-08-25	Durect Corporation	Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
US8486448B2 (en)	2007-12-17	2013-07-16	Paladin Labs Inc.	Misuse preventative, controlled release formulation
US8623418B2 (en) *	2007-12-17	2014-01-07	Alpharma Pharmaceuticals Llc	Pharmaceutical composition
EP2224808A4 (en) *	2007-12-17	2013-11-27	Alpharma Pharmaceuticals Llc	PHARMACEUTICAL COMPOSITION
US20100151014A1 (en) *	2008-12-16	2010-06-17	Alpharma Pharmaceuticals, Llc	Pharmaceutical composition
RU2478388C2 (ru) *	2008-07-07	2013-04-10	Еуро-Селтик С.А.	Фармацевтическая композиция, содержащая опиоидный антагонист, для лечения задержки мочи
US20100260844A1 (en)	2008-11-03	2010-10-14	Scicinski Jan J	Oral pharmaceutical dosage forms
WO2010066034A1 (en) *	2008-12-12	2010-06-17	Paladin Labs Inc.	Methadone formulation
ES2509497T3 (es)	2008-12-16	2014-10-17	Paladin Labs Inc.	Formulación de liberación controlada para evitar un uso indebido
MY152279A (en)	2009-03-10	2014-09-15	Euro Celtique Sa	Immediate release pharmaceutical compositions comprising oxycodone and naloxone
WO2010144865A2 (en)	2009-06-12	2010-12-16	Meritage Pharma, Inc.	Methods for treating gastrointestinal disorders
AU2010300641B2 (en) *	2009-09-30	2016-03-17	Acura Pharmaceuticals, Inc.	Methods and compositions for deterring abuse
US10668060B2 (en)	2009-12-10	2020-06-02	Collegium Pharmaceutical, Inc.	Tamper-resistant pharmaceutical compositions of opioids and other drugs
WO2011106416A2 (en) *	2010-02-24	2011-09-01	Cima Labs Inc.	Abuse-resistant formulations
US9700508B2 (en) *	2010-05-10	2017-07-11	Euro-Celtique S.A.	Pharmaceutical compositions comprising hydromorphone and naloxone
CA2798702A1 (en)	2010-05-11	2011-11-17	Cima Labs Inc.	Alcoholresistant metoprolol-containing extended-release oral dosage forms
US8623409B1 (en)	2010-10-20	2014-01-07	Tris Pharma Inc.	Clonidine formulation
ME02874B (me)	2010-12-22	2018-04-20	Purdue Pharma Lp	Obloženi dozni oblici sa kontrolisanim oslobađanjem otporni na zloupotrebu
PH12013501345A1 (en)	2010-12-23	2022-10-24	Purdue Pharma Lp	Tamper resistant solid oral dosage forms
KR20180027641A (ko)	2011-02-02	2018-03-14	알파마 파머슈티컬스 엘엘씨	오피오이드 효능제 및 격리된 길항제를 포함하는 제약 조성물
EA201400172A1 (ru)	2011-07-29	2014-06-30	Грюненталь Гмбх	Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
BR112014001091A2 (pt)	2011-07-29	2017-02-14	Gruenenthal Gmbh	comprimido resistente à adulteração que fornece liberação imediata do fármaco
AU2012296346A1 (en) *	2011-08-18	2014-04-03	Biodelivery Sciences International, Inc.	Abuse-resistant mucoadhesive devices for delivery of buprenorphine
JP6210988B2 (ja)	2011-09-19	2017-10-11	オレクソ・アクチエボラゲット	オピオイド依存を治療するための新規乱用耐性医薬組成物
WO2013126552A1 (en)	2012-02-21	2013-08-29	Auburn University	Buprenorphine nanoparticle composition and methods thereof
EP2872121B1 (en)	2012-07-12	2018-09-05	SpecGx LLC	Extended release, abuse deterrent pharmaceutical compositions
MX366159B (es)	2012-11-30	2019-07-01	Acura Pharmaceuticals Inc	Liberacion autorregulada de ingrediente farmaceutico activo.
MX2015010041A (es)	2013-02-05	2015-10-30	Purdue Pharma Lp	Formulacion farmaceuticas resistentes a la alteracion.
TW201521769A (zh)	2013-03-15	2015-06-16	Durect Corp	具有流變改質劑以減少溶解變異性之組成物
US10751287B2 (en)	2013-03-15	2020-08-25	Purdue Pharma L.P.	Tamper resistant pharmaceutical formulations
BR112016000194A8 (pt)	2013-07-12	2019-12-31	Gruenenthal Gmbh	forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila
US10071089B2 (en)	2013-07-23	2018-09-11	Euro-Celtique S.A.	Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
CA3042642A1 (en)	2013-08-12	2015-02-19	Pharmaceutical Manufacturing Research Services, Inc.	Extruded immediate release abuse deterrent pill
US20150118300A1 (en)	2013-10-31	2015-04-30	Cima Labs Inc.	Immediate Release Abuse-Deterrent Granulated Dosage Forms
WO2015071380A1 (en)	2013-11-13	2015-05-21	Euro-Celtique S.A.	Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
US10172797B2 (en)	2013-12-17	2019-01-08	Pharmaceutical Manufacturing Research Services, Inc.	Extruded extended release abuse deterrent pill
US9492444B2 (en)	2013-12-17	2016-11-15	Pharmaceutical Manufacturing Research Services, Inc.	Extruded extended release abuse deterrent pill
WO2015089530A1 (de) *	2013-12-20	2015-06-25	G.L. PHARMA GmbH	Orale darreichungsform mit verzögerter freisetzung enthaltend morphin und naloxon
MX2016008361A (es) *	2013-12-23	2016-10-14	Purdue Pharma Lp	Formulaciones de antagonista de opioides.
WO2015145461A1 (en)	2014-03-26	2015-10-01	Sun Pharma Advanced Research Company Ltd.	Abuse deterrent immediate release biphasic matrix solid dosage form
CA2955229C (en)	2014-07-17	2020-03-10	Pharmaceutical Manufacturing Research Services, Inc.	Immediate release abuse deterrent liquid fill dosage form
US9132096B1 (en)	2014-09-12	2015-09-15	Alkermes Pharma Ireland Limited	Abuse resistant pharmaceutical compositions
AU2015336065A1 (en)	2014-10-20	2017-05-04	Pharmaceutical Manufacturing Research Services, Inc.	Extended release abuse deterrent liquid fill dosage form
EP3229785A2 (de) *	2014-12-08	2017-10-18	Develco Pharma Schweiz AG	Naloxon-monopräparat und mehrschichttablette
US11103581B2 (en)	2015-08-31	2021-08-31	Acura Pharmaceuticals, Inc.	Methods and compositions for self-regulated release of active pharmaceutical ingredient
US11590228B1 (en)	2015-09-08	2023-02-28	Tris Pharma, Inc	Extended release amphetamine compositions
JP2018526414A (ja)	2015-09-10	2018-09-13	グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング	乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
US9737530B1 (en)	2016-06-23	2017-08-22	Collegium Pharmaceutical, Inc.	Process of making stable abuse-deterrent oral formulations
SG11201811760VA (en)	2016-07-06	2019-01-30	Durect Corp	Oral dosage form with drug composition, barrier layer and drug layer
WO2018119033A1 (en) *	2016-12-20	2018-06-28	Cima Labs Inc.	Abuse-resistant and abuse-deterrent dosage forms
US12458592B1 (en)	2017-09-24	2025-11-04	Tris Pharma, Inc.	Extended release amphetamine tablets
US11590081B1 (en)	2017-09-24	2023-02-28	Tris Pharma, Inc	Extended release amphetamine tablets
US11324707B2 (en)	2019-05-07	2022-05-10	Clexio Biosciences Ltd.	Abuse-deterrent dosage forms containing esketamine
US12589083B2 (en)	2019-05-07	2026-03-31	Clexio Biosciences Ltd.	Abuse-deterrent dosage forms containing esketamine
US11918689B1 (en)	2020-07-28	2024-03-05	Tris Pharma Inc	Liquid clonidine extended release composition

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1172767A (en) *	1912-12-02	1916-02-22	Levi S Couplin	Fly-trap.
US3773955A (en) *	1970-08-03	1973-11-20	Bristol Myers Co	Analgetic compositions
US3966940A (en) *	1973-11-09	1976-06-29	Bristol-Myers Company	Analgetic compositions
US4457933A (en) *	1980-01-24	1984-07-03	Bristol-Myers Company	Prevention of analgesic abuse
US6022544A (en) *	1983-01-24	2000-02-08	The John Hopkins University	Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US5472943A (en) *	1992-09-21	1995-12-05	Albert Einstein College Of Medicine Of Yeshiva University,	Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
US5512578A (en) *	1992-09-21	1996-04-30	Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University	Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
US20010006967A1 (en) *	1992-09-21	2001-07-05	Stanley M. Crain	Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists
US5580876A (en) *	1992-09-21	1996-12-03	Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University	Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5422943A (en) *	1992-09-30	1995-06-06	At&T Corp.	Private branch exchange networks
US5656291A (en) *	1994-03-16	1997-08-12	Pharmacia & Upjohn Aktiebolag	Controlled release preparation
IL110014A (en) *	1993-07-01	1999-11-30	Euro Celtique Sa	Solid controlled-release oral dosage forms of opioid analgesics
US6210714B1 (en) *	1993-11-23	2001-04-03	Euro-Celtique S.A.	Immediate release tablet cores of acetaminophen having sustained-release coating
US5395626A (en) *	1994-03-23	1995-03-07	Ortho Pharmaceutical Corporation	Multilayered controlled release pharmaceutical dosage form
AUPN603895A0 (en) *	1995-10-19	1995-11-09	University Of Queensland, The	Production of analgesic synergy by co-administration of sub-analgesic doses of two strong opioids
PL188919B1 (pl) *	1996-03-08	2005-05-31	Nycomed Danmark As	Doustna, multijednostkowa kompozycja preparatu farmaceutycznego o modyfikowanym uwalnianiu oraz sposób wytwarzania jednostki dawkowania doustnej multijednostkowej kompozycji farmaceutycznej o modyfikowanym uwalnianiu
DE69709646T2 (de) *	1996-03-12	2002-08-14	Alza Corp., Palo Alto	Zusammensetzung und dosisform mit einem opioid-antagonisten
DE19651551C2 (de) *	1996-12-11	2000-02-03	Klinge Co Chem Pharm Fab	Opioidantagonisthaltige galenische Formulierung
US5885616A (en) *	1997-08-18	1999-03-23	Impax Pharmaceuticals, Inc.	Sustained release drug delivery system suitable for oral administration
ATE265213T1 (de) *	1997-09-04	2004-05-15	Novoneuron Inc	Noribogain zur behandlung von schmerzen und drogenabhängigkeit
CA2314896C (en) *	1997-12-22	2005-09-13	Euro-Celtique, S.A.	A method of preventing abuse of opioid dosage forms
JP2001526228A (ja) *	1997-12-22	2001-12-18	ユーロ−セルティーク，エス．エイ．	オピオイド作動薬／拮抗薬の併用
US6375957B1 (en) *	1997-12-22	2002-04-23	Euro-Celtique, S.A.	Opioid agonist/opioid antagonist/acetaminophen combinations
DE19901687B4 (de) *	1999-01-18	2006-06-01	Grünenthal GmbH	Opioide Analgetika mit kontrollierter Wirkstofffreisetzung
US6451806B2 (en) *	1999-09-29	2002-09-17	Adolor Corporation	Methods and compositions involving opioids and antagonists thereof
US6716449B2 (en) *	2000-02-08	2004-04-06	Euro-Celtique S.A.	Controlled-release compositions containing opioid agonist and antagonist
HU229705B1 (en) *	2000-02-08	2014-05-28	Euro Celtique Sa	Tamper-resistant oral opioid agonist formulations
US20040024004A1 (en) *	2001-05-04	2004-02-05	Sherman Barry M.	Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
US7034036B2 (en) *	2000-10-30	2006-04-25	Pain Therapeutics, Inc.	Inhibitors of ABC drug transporters at the blood-brain barrier
JP2005515960A (ja) *	2001-05-11	2005-06-02	エンドーファーマシューティカルズ，インコーポレイティド	乱用耐性のオピオイド投薬形態
CN1525851A (zh) *	2001-05-11	2004-09-01	��ҩ��޹�˾	抗滥用阿片样物质控释剂型
US20030035839A1 (en) *	2001-05-15	2003-02-20	Peirce Management, Llc	Pharmaceutical composition for both intraoral and oral administration
US20030044458A1 (en) *	2001-08-06	2003-03-06	Curtis Wright	Oral dosage form comprising a therapeutic agent and an adverse-effect agent
AU2002324624A1 (en) *	2001-08-06	2003-02-24	Euro-Celtique S.A.	Sequestered antagonist formulations
ATE431738T1 (de) *	2001-08-06	2009-06-15	Euro Celtique Sa	Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
EP1429744A1 (en) *	2001-09-21	2004-06-23	Egalet A/S	Morphine polymer release system
AU2003301121A1 (en) *	2002-12-18	2004-07-14	Pain Therapeutics, Inc.	Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
US20040202717A1 (en) *	2003-04-08	2004-10-14	Mehta Atul M.	Abuse-resistant oral dosage forms and method of use thereof
CA2548834C (en) *	2003-12-09	2009-08-11	Euro-Celtique S.A.	Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
EP1898891A2 (en) *	2005-05-13	2008-03-19	Alza Corporation	Multilayer drug delivery system with barrier against antagonist exposure
US20070020339A1 (en) *	2005-07-20	2007-01-25	Pharmorx Inc.	Compositions and methods for controlling abuse of medications
US20090022798A1 (en) *	2007-07-20	2009-01-22	Abbott Gmbh & Co. Kg	Formulations of nonopioid and confined opioid analgesics
SI2719378T1 (sl) *	2006-06-19	2016-11-30	Alpharma Pharmaceuticals Llc	Farmacevtski sestavki
EP3090743A1 (en) *	2008-01-09	2016-11-09	Charleston Laboratories, Inc.	Pharmaceutical compositions for treating headache and eliminating nausea

2002
- 2002-05-10 JP JP2002588977A patent/JP2005515960A/ja active Pending
- 2002-05-10 CA CA2446738A patent/CA2446738C/en not_active Expired - Lifetime
- 2002-05-10 WO PCT/US2002/015021 patent/WO2002092059A1/en not_active Ceased
- 2002-05-10 US US10/143,140 patent/US20030004177A1/en not_active Abandoned
- 2002-05-10 CN CNA028097378A patent/CN1592609A/zh active Pending
- 2002-05-10 EP EP02731767A patent/EP1389092B1/en not_active Expired - Lifetime
- 2002-05-10 DE DE60216078T patent/DE60216078T2/de not_active Expired - Lifetime
- 2002-05-10 ES ES02731767T patent/ES2275868T3/es not_active Expired - Lifetime
- 2002-05-10 CA CA2778114A patent/CA2778114A1/en not_active Abandoned
- 2002-05-10 AU AU2002303718A patent/AU2002303718B2/en not_active Expired
- 2002-05-10 CN CNA2008101667341A patent/CN101439024A/zh active Pending
- 2002-05-10 AT AT02731767T patent/ATE345112T1/de not_active IP Right Cessation
2009
- 2009-03-26 JP JP2009077801A patent/JP2009143964A/ja not_active Withdrawn
2010
- 2010-09-30 US US12/894,614 patent/US20110020444A1/en not_active Abandoned
2011
- 2011-02-24 US US13/033,899 patent/US20110135731A1/en not_active Abandoned
2012
- 2012-05-17 US US13/473,946 patent/US20120231075A1/en not_active Abandoned
- 2012-05-25 US US13/480,737 patent/US20120237603A1/en not_active Abandoned
- 2012-12-19 JP JP2012276500A patent/JP2013053165A/ja active Pending
2013
- 2013-02-21 US US13/773,123 patent/US20130209561A1/en not_active Abandoned

Publication	Publication Date	Title
JP2009143964A5 (2)	2010-02-25
JP5566102B2 (ja)	2014-08-06	医薬組成物
US8652529B2 (en)	2014-02-18	Anti-misuse microparticulate oral pharmaceutical form
JP5537030B2 (ja)	2014-07-02	誤用防止微粒子経口医薬形態
JP2013540807A5 (2)	2014-10-09
JP5691051B2 (ja)	2015-04-01	ジオポリマー結合剤を含む持続薬物送達用組成物
JP2010506833A (ja)	2010-03-04	医薬組成物
AU2011263780A1 (en)	2013-01-10	Diversion-resistant microgranules and microtablets
CZ300531B6 (cs)	2009-06-10	Farmaceutická léková forma pro jednotlivé podání a její použití
JP2007530684A (ja)	2007-11-01	吸着剤と逆作用薬とを含有する不正使用防止投与剤型
JP2016516698A5 (2)	2017-04-06
JP2017081942A (ja)	2017-05-18	オピオイドアゴニストおよび隔離されているアンタゴニストを含む医薬組成物
CA2661759A1 (en)	2008-03-06	Buprenophine-wafer for drug substitution therapy
RU2013117274A (ru)	2014-12-10	Композиции и способы для смягчения дыхательной недостаточности, вызванной передозировкой опиоидов
CA2709905A1 (en)	2009-06-25	Abuse-resistant oxycodone composition
JP2011137020A5 (2)	2012-02-16
WO2007123865A3 (en)	2008-07-31	Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists
JP2012087101A (ja)	2012-05-10	オピオイドおよびオピオイド拮抗薬を含む微粒子医薬組成物
JP2013537915A (ja)	2013-10-07	オピオイドの制御放出製剤
JP2012524732A (ja)	2012-10-18	オピオイドおよびオピオイド拮抗薬を含む微粒子医薬組成物
CN1691936A (zh)	2005-11-02	立即释放和延长释放组合的镇痛药组合物
HRP20100373T4 (hr)	2016-12-16	Upotreba kombinacije morfina s najmanje jednim opijatnim antagonistom u liječenju ovisnosti o opijatima i u sprječavanju neoralne zloupotrebe opijata kod ovisnika opijatima
JP2018515619A5 (2)	2019-06-13
JP2018515456A5 (2)	2019-05-30
RU2003135201A (ru)	2005-03-27	Применение антагониста опиоидов налтрексона для предупреждения и контроля побочных воздействий, вызванных опиоидами